Skip to main content
    L

    LifeMD Inc (LFMD)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $1.85
    -0.34 (-15.72%)

    Market Cap: $106.09M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    LifeMD Inc (LFMD) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    LifeMD (LFMD) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, LifeMD reported EPS of -$0.11, above the -$0.14 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    52%(13/25)
    Avg Surprise
    -47.44%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.20 - $0.06
    10 analysts
    Revenue Consensus
    $51.69M
    Range$45.18M - $65.10M
    10 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.09
    Range$0.09 - $0.09
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.13-30.8%
    60d ago$0.11-18.2%
    30d ago$0.11-18.2%
    7d ago$0.11-18.2%
    Current$0.09
    Revenue Consensus
    $55.59M
    Range$50.66M - $60.28M
    6 analysts

    Next Report

    LFMD has an expected report date of Mar 8, 2027.

    LFMD Earnings Call

    The latest LFMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 25 quarters below that had an estimate, LFMD beat 13, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $44.63M, down 6.5% from $47.73M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.11-$0.14N/A+21.43%BeatN/A20 up, 1 downNov 12, 2026$44.63M
    Jun 30, 2026-$0.15-$0.04-$0.09 - $0.00-275.00%MissN/A20 up, 1 downAug 5, 2026$47.28M
    Mar 31, 2026-$0.15-$0.12-$0.13 - -$0.12-29.91%Miss-605.3%20 up, 1 downMay 6, 2026$50.16M
    Dec 31, 2025$0.06$0.09-$0.08 - $0.15-33.33%Miss-71.4%30 up, 1 downMar 9, 2026$46.87M
    Sep 30, 2025-$0.08$0.05-$0.04 - $0.13-260.00%Miss-188.9%20 up, 1 downNov 17, 2025$47.73M
    Jun 30, 2025-$0.01$0.18$0.18 - $0.18-105.56%Miss-116.7%11 up, 0 downAug 4, 2025$49.02M
    Mar 31, 2025$0.03$0.14$0.14 - $0.14-78.57%Miss+200.0%10 up, 1 downMay 6, 2025$50.89M
    Dec 31, 2024$0.21$0.14$0.14 - $0.14+50.00%BeatN/A10 up, 1 downMar 10, 2025$64.25M
    Sep 30, 2024$0.09$0.07N/A+28.57%Beat+12.5%60 up, 0 downNov 7, 2024$53.27M
    Jun 30, 2024$0.06$0.04N/A+50.00%Beat+20.0%40 up, 0 downAug 7, 2024$50.66M
    Mar 31, 2024$0.01-$0.01N/A+200.00%BeatN/A50 up, 0 downMay 8, 2024$44.14M
    Dec 31, 2023-$0.12-$0.14-$0.16 - -$0.12+14.29%BeatN/A50 up, 0 downMar 11, 2024$44.86M
    Sep 30, 2023$0.08$0.03N/A+166.67%BeatN/A40 up, 0 downNov 8, 2023$38.61M
    Jun 30, 2023$0.05$0.03N/A+66.67%BeatN/A30 up, 0 downAug 9, 2023$35.95M
    Mar 31, 2023-$0.15-$0.16-$0.16 - -$0.16+6.25%BeatN/A11 up, 0 downMay 12, 2023$33.13M
    Dec 31, 2022-$0.40-$0.18-$0.18 - -$0.18-122.22%MissN/A10 up, 0 downMar 22, 2023$28.12M
    Sep 30, 2022-$0.03-$0.12N/A+75.00%BeatN/A20 up, 0 downNov 10, 2022$31.41M
    Jun 30, 2022-$0.22-$0.23N/A+4.35%BeatN/A20 up, 0 downAug 11, 2022$30.46M
    Mar 31, 2022-$0.46-$0.36-$0.41 - -$0.32-27.78%MissN/A20 up, 1 downMay 13, 2022$29.04M
    Dec 31, 2021-$0.29-$0.39-$0.49 - -$0.36+25.64%BeatN/A20 up, 0 downMar 7, 2022$27.42M
    Sep 30, 2021-$0.36-$0.49N/A+26.53%BeatN/A2N/ANov 10, 2021$24.95M
    Jun 30, 2021-$0.51-$0.45N/A-13.33%MissN/A2N/AAug 12, 2021$22.31M
    Mar 31, 2021-$0.48-$0.44-$1.03 - -$0.32-9.09%MissN/A2N/AMay 13, 2021$18.20M
    Dec 31, 2020-$2.56-$0.24-$0.27 - -$0.22-966.67%MissN/A2N/AMar 29, 2021$12.89M
    Sep 30, 2020-$1.03-$1.03N/A0.00%In lineN/AN/AN/ANov 16, 2020$11.01M
    Jun 30, 2020-$2.54N/AN/AN/AN/AN/AN/AN/AAug 14, 2020$9.09M
    Mar 31, 2020-$0.22N/AN/AN/AN/AN/AN/AN/AMay 19, 2020$4.30M
    Dec 31, 2019-$0.07N/AN/AN/AN/AN/AN/AN/AMar 30, 2020$3.94M
    Sep 30, 2019-$0.09N/AN/AN/AN/AN/AN/AN/ANov 14, 2019$3.13M
    Jun 30, 2019-$0.09N/AN/AN/AN/AN/AN/AN/AAug 14, 2019$2.70M
    Mar 31, 2019-$0.07N/AN/AN/AN/A-204.6%N/AN/AMay 15, 2019$2.70M
    Dec 31, 2018-$0.09N/AN/AN/AN/AN/AN/AN/AMar 29, 2019$2.18M
    Sep 30, 2018-$0.06N/AN/AN/AN/AN/AN/AN/ANov 14, 2018$2.50M
    Jun 30, 2018-$0.07N/AN/AN/AN/A-190.1%N/AN/AAug 17, 2018$2.04M
    Mar 31, 2018$0.07N/AN/AN/AN/AN/AN/AN/AApr 2, 2018$1.61M
    Dec 31, 2017-$0.03N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$802107
    Sep 30, 2017-$0.08N/AN/AN/AN/AN/AN/AN/ANov 14, 2017$2.05M
    Jun 30, 2017$0.08N/AN/AN/AN/AN/AN/AN/AJul 7, 2017$660087
    Mar 31, 2017-$0.14N/AN/AN/AN/AN/AN/AN/AMar 31, 2017$167899
    Dec 31, 2016-$0.09N/AN/AN/AN/AN/AN/AN/ADec 31, 2016$985900
    Last 40 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Dec 31, 2025Not reportedN/A
    Dec 31, 2024$0.37N/A
    Dec 31, 2023-$0.14N/A
    Dec 31, 2022-$1.11N/A
    Dec 31, 2021-$1.64N/A
    Dec 31, 2020-$6.35N/A
    Dec 31, 2019-$0.32N/A
    Dec 31, 2018-$0.14N/A
    Dec 31, 2017-$0.16N/A
    Dec 31, 2016-$0.16N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,500 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,5207
    2026Q2Jun 30, 20267,1357
    2026Q1Mar 31, 20265,2869
    2025Q4Dec 31, 20254,6628
    2025Q3Sep 30, 20255,9928
    2025Q2Jun 30, 20254,7189
    2025Q1Mar 31, 20254,3189
    2024Q3Sep 30, 20245,7368

    2026Q3 Earnings Call

    Opening remarks

    Justin Schreiber Chairman and CEO Thank you, operator, and good afternoon, everyone. Earlier this afternoon, we issued our third quarter release and filed our 10-Q. Let me start with the numbers. Revenue was $44.6 million, below the range we guided to. Adjusted EBITDA was slightly negative within our guidance range and a $3.1 million improvement over the second quarter. We are also resetting our outlook for the fourth quarter and the full year. Last quarter, I told you we expected to exit the year at a $250 million revenue run rate. We won't. We now expect to exit at roughly a $200 million revenue run rate. There were three things that drove the shortfall. First, our guidance assumed our branded GLP-1 fulfillment program would begin earlier in the quarter. Finalizing and implementing those arrangements took longer than we planned, so less of that revenue landed in the third quarter. This was a timing issue, not a demand issue. Arrangements with manufacturers are now in place and the program is ramping, as I'll discuss in a moment. Second, we took a conservative approach to new patient acquisition. We cut marketing spend by almost one-third quarter-over-quarter, while we improved our technology platform and patient experience to drive better unit economics and patient retention. We also chose longer patient subscription commitments over upfront revenue. Those choices cost us revenue this quarter. Third, and this is related to the second, some of the patient cohorts we brought on earlier this year didn't perform the way we expected. This is a big part of why we pulled back. We made pricing and plan changes to address that, and rather than scale spend before we knew those changes were working, we chose to hold back until our new cohorts proved out. The early results are encouraging, and I'll come back to those shortly. The most important takeaway for our shareholders is that despite some continued softness in the business, we are in a strong liquidity position and I believe we have an amazing year of high-quality growth ahead of us. I'm going to keep the rest of my remarks short because the message is simple. It comes down to five things. First, we are more confident than ever in our decision to build LifeMD's weight management offering around branded GLP-1s. In the last 30 days, we completed arrangements with both Eli Lilly and Novo Nordisk that enable us to integrate self-pay GLP-1 medications directly into our pharmacy operations, further expanding access to these products by removing friction from the patient experience. Second, our enterprise business is off to a strong start.

    Frequently Asked Questions About LFMD

    When is LifeMD's next earnings date?

    LifeMD's next earnings report is expected for Mar 8, 2027.

    Did LFMD beat earnings estimates last quarter?

    Yes. LifeMD reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 21.43% surprise.

    What EPS do analysts expect from LFMD next quarter?

    The consensus EPS estimate for LifeMD for the quarter ending Dec 31, 2026 is -$0.09 from 10 analysts, with estimates from -$0.20 to $0.06.

    How often does LFMD beat earnings estimates?

    LifeMD beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -88.87%.